+

WO2006033012A3 - Procede - Google Patents

Procede Download PDF

Info

Publication number
WO2006033012A3
WO2006033012A3 PCT/IB2005/003070 IB2005003070W WO2006033012A3 WO 2006033012 A3 WO2006033012 A3 WO 2006033012A3 IB 2005003070 W IB2005003070 W IB 2005003070W WO 2006033012 A3 WO2006033012 A3 WO 2006033012A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
virus infection
modulators
screening
agent
Prior art date
Application number
PCT/IB2005/003070
Other languages
English (en)
Other versions
WO2006033012A2 (fr
Inventor
Romuald Gaston Corbau
Derek John Falconer
Helen Bostock Lavender
Manoussos Perros
Original Assignee
Pfizer Ltd
Pfizer
Romuald Gaston Corbau
Derek John Falconer
Helen Bostock Lavender
Manoussos Perros
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0421360A external-priority patent/GB0421360D0/en
Application filed by Pfizer Ltd, Pfizer, Romuald Gaston Corbau, Derek John Falconer, Helen Bostock Lavender, Manoussos Perros filed Critical Pfizer Ltd
Publication of WO2006033012A2 publication Critical patent/WO2006033012A2/fr
Publication of WO2006033012A3 publication Critical patent/WO2006033012A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé de dosage et des composés destinés au traitement d'une infection par le virus de l'hépatite C. Le procédé de dosage selon l'invention est notamment destiné à déterminer si un agent est capable de moduler une infection par le virus de l'hépatite C (HCV). Ledit procédé consiste (a) à amener l'agent en contact avec (i) une première lignée cellulaire exprimant des protéines E1 et E2 sur la surface de la cellule et (ii) une deuxième lignée cellulaire permissive ; et (b) à déterminer si l'agent inhibe la fusion entre la première et la deuxième lignée cellulaire, les protéines E1 et E2 étant des protéines de longueur totale.
PCT/IB2005/003070 2004-09-24 2005-09-19 Procede WO2006033012A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0421360.9 2004-09-24
GB0421360A GB0421360D0 (en) 2004-09-24 2004-09-24 Method
US62237704P 2004-10-26 2004-10-26
US60/622,377 2004-10-26

Publications (2)

Publication Number Publication Date
WO2006033012A2 WO2006033012A2 (fr) 2006-03-30
WO2006033012A3 true WO2006033012A3 (fr) 2006-08-24

Family

ID=36090386

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/003070 WO2006033012A2 (fr) 2004-09-24 2005-09-19 Procede

Country Status (1)

Country Link
WO (1) WO2006033012A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009030872A1 (fr) * 2007-09-07 2009-03-12 Mats Axel Atterdag Persson Matériaux et procédés pour le traitement de l'hépatite c
JP6110846B2 (ja) * 2011-05-27 2017-04-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤としての重水素が導入されたトリペプチド
CN105330730A (zh) * 2014-07-29 2016-02-17 中国科学院上海巴斯德研究所 一种丙型肝炎病毒重组蛋白的制备及其应用
CN114062070A (zh) * 2021-09-27 2022-02-18 苏州德运康瑞生物科技有限公司 用于制备循环肿瘤细胞质控品的试剂盒及循环肿瘤细胞质控品的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020160936A1 (en) * 1999-09-29 2002-10-31 Howard J. Worman Hcv e2 protein binding agents for treatment of hepatitis c virus infection
EP1267167A1 (fr) * 2001-06-15 2002-12-18 Pfizer Limited Procédé pour l'identification des facteurs de pénétration de HCV
US20030129746A1 (en) * 1998-03-27 2003-07-10 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
US6635257B1 (en) * 1998-06-24 2003-10-21 Innogentics N.V. Particles of HCV envelope proteins: use for vaccination
US20040115619A1 (en) * 2000-12-01 2004-06-17 Darren Schofield Monoclonal antibodies specific for the e2 glycoprotein of hepatitic c virus and their use in the diagnosis, treatment , and prevention of hepatitis c

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129746A1 (en) * 1998-03-27 2003-07-10 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
US6635257B1 (en) * 1998-06-24 2003-10-21 Innogentics N.V. Particles of HCV envelope proteins: use for vaccination
US20020160936A1 (en) * 1999-09-29 2002-10-31 Howard J. Worman Hcv e2 protein binding agents for treatment of hepatitis c virus infection
US20040115619A1 (en) * 2000-12-01 2004-06-17 Darren Schofield Monoclonal antibodies specific for the e2 glycoprotein of hepatitic c virus and their use in the diagnosis, treatment , and prevention of hepatitis c
EP1267167A1 (fr) * 2001-06-15 2002-12-18 Pfizer Limited Procédé pour l'identification des facteurs de pénétration de HCV

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAKIKAWA SHINGO ET AL: "Cell fusion activity of hepatitis C virus envelope proteins", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 11, June 2000 (2000-06-01), pages 5066 - 5074, XP002197964, ISSN: 0022-538X *

Also Published As

Publication number Publication date
WO2006033012A2 (fr) 2006-03-30

Similar Documents

Publication Publication Date Title
WO2005012872A3 (fr) Detection d'analyte a base de cristaux liquides
BRPI0516356A (pt) terapia à base de levedura para infecções crÈnicas da hepatite c
ID26073A (id) Metode pendeteksi status konsumsi cairan, wadah cairan dan selongsong tinta
NO20016243D0 (no) Anti-alfav-beta3-rekombinante humane antistoffer, nukleinsyrer som koder for de samme og fremgangsmåter foranvendelse
WO2001057194A3 (fr) Molecules d'acides nucleiques codant pour des proteases a serine transmembranaires, proteines codees et procedes associes
WO2005032487A3 (fr) Enzyme de conversion de l'angiotensine 2 comme recepteur du coronavirus sras
WO2006093797A3 (fr) Procede et trousses de materiel permettant la detection du virus du syndrome dysgenesique et respiratoire du porc
WO2010074575A3 (fr) Virus de la peste porcine classique (vppc) recombiné comprenant une protéine e2 modifiée et procédés de production dudit vppc recombiné
ATE481494T1 (de) Von rna viren abgeleitetes pflanzenexpressionssystem aus zwei komponenten
WO2007003324A3 (fr) Greffon acellulaire
WO2005087931A8 (fr) Virus oncolytiques modifies
WO2005087951A3 (fr) Reactifs, procedes et kits utilise dans la desactivation d'acides nucleiques
WO2004016586A3 (fr) Compositions et methodes associees aux antigenes de domaine iii de la proteine d'enveloppe du flavivirus
WO2005071414A3 (fr) Trousse permettant d'immobiliser une substance organique, structure a substance organique immobilisee, et procedes de fabrication correspondants
WO2006033012A3 (fr) Procede
WO2004060303A3 (fr) Procedes et reactifs pour l'amelioration de la transduction virale dans l'epithelium de la vessie
WO2006038129A3 (fr) Systeme de replication du virus de l'hepatite c
WO2005063801A3 (fr) Particules du type coronavirus comprenant des genomes a deletions fonctionnelles
WO2003059943A3 (fr) Peptides specifiques a la conformation, de liaison de la proteine kinase, procedes et produits associes
WO2002088338A3 (fr) Procede de replication du virus de l'hepatite c
WO2002100900A3 (fr) Anticorps humain recombine dirige contre la proteine non structurale ns3 de l'hepatite c (vhc), acide nucleique et ses utilisations
WO2001068818A3 (fr) Fragments de ns 2/3 du vhc et leurs utilisations
WO2006002141A3 (fr) Detection de peptides a modification post-translationnelle a l'aide de cristaux liquides
WO2002002631A8 (fr) Mise au point structurale de medicaments contre le virus de l'hepatite c
WO2004104033A3 (fr) Virus dependant d'agents d'induction pour entree virale dans une cellule hote

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载